Biotech Startups

Neuvasq Biotechnologies is a biotech spin-off from the Université libre de Bruxelles developing therapies that target the Gpr124/Reck signaling complex to repair the blood-brain and blood-CNS barriers in neurological and cerebrovascular disorders. The company translates research on brain vasculature and the blood-brain barrier into drug development programs.

1 investor

NeuWave Medical develops the NeuWave Microwave Ablation System, a device used by healthcare professionals to ablate soft tissue, including non-resectable liver tumors, in percutaneous, open surgical, and laparoscopic settings. The system includes a probe portfolio and ABLATE-IQ software for margin confirmation, and is marketed for use in the United States; the company is a wholly owned subsidiary of Quantum Surgical, Inc.

1 investor

Neva SGR is the venture capital arm of Italy's Intesa Sanpaolo Group, investing through funds such as Neva First and Neva II in startups across life sciences, climate tech, digital transformation, and aerospace. It backs portfolio companies globally and provides business development support to help them expand internationally.

1 investor

New Dawn Bio produces wood grown through cell culture rather than harvested from trees. The company applies biotechnology to create cultured wood materials.

1 investor

New Life Minds develops technology combining healthcare, life sciences, synthetic biology, and machine learning, with a stated focus on advancing brain evolution.

1 investor

New West Genetics breeds non-GMO industrial hemp seed varieties, using traditional breeding and genomics to create regionally adapted, high-yield genetics for grain, fiber, feed, and fuel applications. Its products, including the ABOUND multi-purpose varieties and AMPLIFY hybrid trait, are sold to hemp growers and agricultural producers, primarily in the United States.

1 investor

An independent nonprofit academic research institution that convenes talent from academic, research, and medical institutions to advance collaborative genomic research and accelerate discoveries in the genetic basis of disease for clinical diagnosis and treatment.

1 investor

New Zealand Clinical Research (NZCR) is a clinical trials and medical research organization that conducts early-phase and later-phase clinical research for pharmaceutical, biotech, and contract research organizations. With over 35 years of experience and multiple facilities across New Zealand, the organization specializes in testing new medicines and treatments across various therapeutic areas including gene therapy, hepatology, and vaccines.

1 investor

New Era develops sustainable colour solutions using biotechnology. The company serves industries requiring clean and clear colour products.

1 investor

Newlight uses ocean microorganisms to convert air and methane-based greenhouse gas into PHB, a biodegradable material it calls AirCarbon that can be molded into shapes, fibers, and sheets. The company applies this technology to produce materials aimed at addressing plastic pollution and climate change.

1 investor

NewMoo produces dairy proteins grown inside plants using molecular science, offering animal-free alternatives to traditional milk proteins for food brands. The product is designed to reduce land use, water consumption, and greenhouse gas emissions compared to conventional dairy.

1 investor

Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.

1 investor

NexCure partners with health systems to build and operate outpatient treatment centers focused on delivering advanced cancer therapies such as CAR-T and T-cell engagers. Its platform combines AI-powered patient selection, remote monitoring, and standardized clinical protocols to bring these treatments to patients in outpatient settings across the country.

1 investor

1 investor

Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays. The company's technology enables faster and more efficient separation and analysis of cells and molecules through reversible phase transitions triggered by temperature, pH, or salt changes.

1 investor

Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches. The company serves patients by translating novel scientific targets into therapeutic candidates.

1 investor

A biotechnology company developing patent-pending technology to combat antibiotic resistance by targeting bacterial resistance mechanisms and restoring the effectiveness of existing antibiotics.

1 investor

NextGen Jane runs a longitudinal molecular study of women's menstruation, using an at-home organic cotton tampon collection kit that members mail in to derive genomic insights from uterine samples. The company aims to improve diagnostics and treatment for gynecological conditions such as endometriosis and other menstrual and reproductive health issues.

1 investor

NEXT NEW WORLD is a Japanese company developing silk protein technology, centered on its patented "Karada Silk" process that turns silk into a water-soluble solution while preserving its nano-scale porous structure for adsorption and cosmetic benefits. It applies this material to healthcare, food, cosmetics, and materials markets through joint research with universities and research institutions in Japan and abroad.

1 investor

NextPharma is a European contract development and manufacturing organization (CDMO) providing pharmaceutical development, clinical trials supply, commercial manufacturing and packaging, analytical and microbiological services, and food supplement production. It serves pharmaceutical and nutrition companies developing and manufacturing drugs and food supplements for worldwide markets.

1 investor

Nexture Bio develops the Doselet, a plant-based dissolvable nanofiber patch for oral nutraceutical delivery, applied to the inner cheek. Its first product delivers 10mg of NAD+ as an alternative to pills or injections for consumer wellness.

1 investor

NF2 Therapeutics (NF2Tx) is a biotech company developing therapies for neurofibromatosis 2 related schwannomatosis (NF2) and related disorders, including an antibody drug conjugate targeting meningiomas and an AAV-based gene therapy for vestibular schwannomas. It works with patients, physicians, and researchers to develop treatments for these rare genetic disorders.

1 investor

nference transforms unstructured biomedical data from electronic medical records into technological solutions that enable scientific discovery of diagnostics and treatments. The company partners with medical centers to synthesize healthcare data for personalized medicine research.

1 investor

nference works with medical centers to transform unstructured data from electronic medical records into tools that help scientists discover and develop personalized diagnostics and treatments. It serves biomedical researchers and healthcare organizations by curating and synthesizing biomedical data for scientific discovery.

1 investor